Title:
FC VARIANT WITH ENHANCED BINDING TO VARIOUS FC GAMMA RECEPTORS
Document Type and Number:
WIPO Patent Application WO/2023/043125
Kind Code:
A1
Abstract:
The present invention relates to an aglycosylated Fc variant with improved binding ability to various Fc-gamma variants, i.e., FcγRⅡa, FcγRⅢa, and FcγRⅡb. Human antibody Fc domain variants of the present invention have improved binding ability not only to FcγRⅡa and FcγRⅢa that are activating receptors, but to FcγRⅡb that is an inhibitory Fc receptor, among Fc-gamma receptors, and particularly, have significantly increased binding ability to FcγRⅡb, and thus can be used as antibody drugs useful for apoptosis of target cells that require a low A/I ratio. As an aglycosylated variant, it has no problem with glycan heterogeneity of a protein therapeutic agent, and mass production of the variant is inexpensive and easy even in bacteria, resulting in the effect of enabling the manufacture of biopharmaceuticals without problems caused by cell lines, culture processes, and purification processes.
Inventors:
JUNG SANG TAEK (KR)
JO MIGYEONG (KR)
JO MIGYEONG (KR)
Application Number:
PCT/KR2022/013489
Publication Date:
March 23, 2023
Filing Date:
September 07, 2022
Export Citation:
Assignee:
UNIV KOREA RES & BUS FOUND (KR)
International Classes:
C07K16/28; A61K39/00; A61P35/00
Domestic Patent References:
| WO2004099249A2 | 2004-11-18 |
Foreign References:
| KR20180051100A | 2018-05-16 | |||
| KR20190044348A | 2019-04-30 | |||
| KR20180046179A | 2018-05-08 |
Other References:
DATABASE PROTEIN ANONYMOUS : "Chain A, Ig gamma-1 chain C region", XP093048520, retrieved from NCBI
Attorney, Agent or Firm:
WIE, Byoung-Gap (KR)
Download PDF:
Previous Patent: GLYCATED FC VARIANTS WITH IMPROVED BINDING AFFINITY FOR FCγRIIIA
Next Patent: CLEAR COAT COMPOSITION
Next Patent: CLEAR COAT COMPOSITION